Tamoxifen

Patients with breast cancer who developed tamoxifen-associated uterine cancer had fewer phosphatidylinositol 3-kinase pathway mutations than those with de novo cases, according to results presented at San Antonio Breast Cancer Symposium.

Safe and effective treatments are available for women who experience sexual dysfunction because of breast cancer care, according to a presentation during the NAMS Annual Meeting.

Medication can play an essential role in breast cancer prevention, Holly J. Pederson, MD, director of medical breast services at the Cleveland Clinic, said during the NAMS Annual Meeting.

The virtual format of this year’s San Antonio Breast Cancer Symposium had its negatives, like missing discussions with colleagues, and its positives, according to Elias Obeid, MD, MPH.

In this video, Elias Obeid, MD, MPH, discussed treatment patterns and clinical outcomes of patients with germline BRCA1/2-mutated, HER2-positive advanced breast cancer.

In this video, Halle Moore, MD, discussed preventive breast cancer treatments for patients who are postmenopausal and have locally excised ductal carcinoma in-situ.

Increasing tamoxifen dosage did not lead to a higher rate of 6-month PFS among patients with hormone receptor-positive metastatic breast cancer who have CYP2D6-variant alleles, according to results of a randomized phase 2 study.

SAN DIEGO — The 2016 recommendations by the American Academy of Ophthalmology on “proper” dosage of hydroxychloroquine lacked essential input from rheumatologists who rely on the drug to improve survival in patients with systemic lupus erythematosus, according to a presentation at the 2019 Congress of Clinical Rheumatology West.